Contraindications while taking evantuzumab/Carestream

Evantumumab (amivantamab) is a dual-target antibody drug. Although it has good efficacy and tolerability, there are still certain contraindications and precautions during use, especially in combination treatment for non-small cell lung cancer or special groups. Understanding medication contraindications is critical to ensuring efficacy and safety.

First, evantumumab is contraindicated in patients with a history of severe allergy to the active ingredient or its excipients. Because it is a humanized antibody, a very small number of people may experience an allergic reaction or an infusion-related reaction manifesting as shortness of breath, low blood pressure, or rash. Therefore, the first dose should be administered in a hospital with emergency conditions and closely monitored by a professional doctor. If a serious infusion reaction occurs, administration should be stopped immediately and corresponding treatment measures should be taken.

Secondly, pregnant and lactating women should avoid using evantumumab. There is currently no sufficient research to show the safety of this drug on fetuses, and animal experiments suggest it may affect embryonic development. Therefore, women of childbearing age should undergo a pregnancy test before taking the drug and take reliable contraceptive measures during treatment. At the same time, because the drug may be excreted through breast milk, lactating patients are advised to temporarily interrupt breastfeeding to prevent affecting the health of the baby.

In addition, patients with severe liver and kidney dysfunction should be cautious when using this drug. Although it has not been clearly shown that evantuzumab causes obvious toxicity in this group of people, its metabolism and elimination mechanism may be affected, so doctors usually adjust the medication cycle or dosage according to the patient's physical condition.

Patients should also avoid taking other strong immunosuppressive drugs at the same time during medication to prevent the immune system from being double suppressed and increasing the risk of infection. If concomitant use of medications is necessary, risk assessment and monitoring should be performed by a physician. In summary, as a new antibody drug, the safety of evantumumab is generally controllable, but it still needs to be used under strict medical supervision.

Reference materials:https://www.rybrevant.com/